Publication:
Chitosan-based delivery of CRISPR-Cas9 plasmid in breast cancer stem cells

Simple item page
dc.contributor.authorEKENTOK ATICI, CEYDA
dc.contributor.authorÖZBAŞ, SUNA
dc.contributor.authorsCanak-Ipek T., Avci-Adali M., EKENTOK ATICI C., ŞALVA E., ÖZBAŞ S.
dc.date.accessioned2023-02-20T10:42:54Z
dc.date.available2023-02-20T10:42:54Z
dc.date.issued2023-01-01
dc.description.abstract© 2023 Marmara University Press.Clustered regularly interspaced short palindromic repeat (CRISPR)-associated Cas9 nuclease system (CRISPR/Cas9) has emerged as a powerful toolbox for cancer therapy, serving as a gene fixed-point knock-out method. However, suitable gene carrier systems are urgently needed to encapsulate the CRISPR/Cas9 system and to improve the uptake into the cancer cells for anti-cancer therapy. In cancer therapy, breast cancer stem cells should be also targeted besides tumor cells. In this study, we prepared chitosan/CRISPR-Cas9/protamine nanoplexes and performed in vitro characterization. The results showed that the chitosan/protamine complex increased the zeta potential of the VEGF CRISPR/Cas9 plasmid from negative to positive. In vitro cell culture studies showed that VEGF silencing efficiency was 46.19% and 30.2% in MCF-7 and MCF-7s, respectively, after 7 days. The invasion capacity of cancer cells decreased significantly for both cell types. The results indicate that chitosan/VEGF CRISPR/Cas9 plasmid/protamine complexes can be used to reduce VEGF expression, leading to a decrease in the invasion capacity of breast cancer as well as breast cancer stem cells and providing proof of concept for more advanced studies, including in vivo studies, of this system.
dc.identifier.citationCanak-Ipek T., Avci-Adali M., EKENTOK ATICI C., ŞALVA E., ÖZBAŞ S., "Chitosan-based delivery of CRISPR-Cas9 plasmid in breast cancer stem cells", Journal of Research in Pharmacy, cilt.27, sa.1, ss.86-96, 2023
dc.identifier.doi10.29228/jrp.292
dc.identifier.endpage96
dc.identifier.issn2630-6344
dc.identifier.issue1
dc.identifier.startpage86
dc.identifier.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85147295633&origin=inward
dc.identifier.urihttps://hdl.handle.net/11424/286586
dc.identifier.volume27
dc.language.isoeng
dc.relation.ispartofJournal of Research in Pharmacy
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectTemel Eczacılık Bilimleri
dc.subjectEczacılık
dc.subjectYaşam Bilimleri
dc.subjectSağlık Bilimleri
dc.subjectTemel Bilimler
dc.subjectBasic Pharmaceutics Sciences
dc.subjectPharmacology and Therapeutics
dc.subjectLife Sciences
dc.subjectHealth Sciences
dc.subjectNatural Sciences
dc.subjectYaşam Bilimleri (LIFE)
dc.subjectFarmakoloji ve Toksikoloji
dc.subjectFARMAKOLOJİ VE ECZACILIK
dc.subjectLife Sciences (LIFE)
dc.subjectPHARMACOLOGY & TOXICOLOGY
dc.subjectPHARMACOLOGY & PHARMACY
dc.subjectGenel Farmakoloji, Toksikoloji ve Eczacılık
dc.subjectFarmakoloji (tıbbi)
dc.subjectGeneral Pharmacology, Toxicology and Pharmaceutics
dc.subjectPharmacology (medical)
dc.subjectbreast cancer
dc.subjectbreast cancer stem cells
dc.subjectchitosan/protamine
dc.subjectCRISPR-Cas9
dc.subjectVEGF
dc.titleChitosan-based delivery of CRISPR-Cas9 plasmid in breast cancer stem cells
dc.typearticle
dspace.entity.typePublication
local.avesis.id38d4b2a0-29cc-4c7b-96fd-7cbefbc80189
local.indexed.atSCOPUS
relation.isAuthorOfPublication95c5df29-d28e-4ce3-a492-e48a561b3dd6
relation.isAuthorOfPublicationd56d5fb1-37ec-4be6-8156-b58d67614019
relation.isAuthorOfPublication.latestForDiscovery95c5df29-d28e-4ce3-a492-e48a561b3dd6

Files

Collections

Research Outputs